Raptor Pharmaceutical has engaged Cambrex to manufacture of the API and Patheon to produce the commercial product for its DR Cysteamine its nephropathic cystinosis treatment.
Raptor Pharmaceutical
Tuesday, 11 January 2011
Raptor engages Cambrex and Patheon
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment